Prospects for the use of biochemical markers in placental in-growth

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Placental in-growth is a severe obstetric pathology characterized by invasive placentation and associated with a high-risk of life-threatening hemorrhage. Despite the widespread use of instrumental methods of examination, timely diagnosis of placental in-growth is a challenging issue. Here, we reviewed the existing biochemical markers used for early detection and confirmation of placental in-growth, their specificity and sensitivity, and correlation with gestational age. Significant results were found for the following substances: pregnancy-associated plasma protein A (PAPP-A) in the first trimester, alpha-fetoprotein (AFP) and human beta-chorionic gonadotropin (Beta-hCG) in the second trimester, brain natriuretic peptide, antithrombin III, plasminogen activator inhibitor type I, soluble Tie-2 receptor (endothelial cell-specific tyrosine kinase receptor), and soluble vascular endothelial growth factor receptor-2. Our findings support the use of the aforementioned biomarkers as screening method for placental in-growth in medical practice.

Full Text

Restricted Access

About the authors

Al’fiya G. Yashchuk

Bashkir State Medical University

Email: alfiya_galimovna@mail.ru
ORCID iD: 0000-0003-2645-1662

MD, Dr. Sci. (Med.), Professor

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

Il’nur I. Musin

Bashkir State Medical University

Email: ilnur-musin@yandex.ru
ORCID iD: 0000-0001-5520-5845

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

Ehdvard A. Berg

Bashkir State Medical University

Email: nucleardeer@gmail.com
ORCID iD: 0000-0002-2028-7796

Assistant Lecturer

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

Dar’ya D. Gromenko

Bashkir State Medical University

Author for correspondence.
Email: dasha.gromenko@mail.ru
ORCID iD: 0000-0001-5638-1779

student

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

Aliya R. Yanbarisova

Bashkir State Medical University

Email: yanbarisova1999@mail.ru
ORCID iD: 0000-0003-3799-4080

student

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

Ivan D. Gromenko

Bashkir State Medical University

Email: z28ivan@mail.ru
ORCID iD: 0000-0001-8582-660X

Assistant Lecturer

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

Ehnzhe F. Berdigulova

Bashkir State Medical University

Email: berdigulova_enzhe@mail.ru
ORCID iD: 0000-0002-5111-0256

student

Russian Federation, 3, Lenin str., Ufa, Republic of Bashkortostan, 450008

References

  1. Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol. 2012;120(1):207–211. doi: 10.1097/AOG.0b013e318262e340
  2. Higgins MF, Monteith C, Foley M, O’Herlihy C. Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):54–56. doi: 10.1016/j.ejogrb.2013.08.030
  3. Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol. 2011;38(2):285–296. doi: 10.1016/j.clp.2011.03.010
  4. Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Main indicators of maternal and child health, the service activities of child welfare and obstetrics in the Russian Federation. Moscow; 2018. (In Russ).
  5. Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Main indicators of maternal and child health, the service activities of child welfare and obstetrics in the Russian Federation. Moscow; 2019. (In Russ).
  6. Publications Committee, Society for Maternal-Fetal Medicine; Belfort MA. Placenta accreta. Am J Obstet Gynecol. 2010;203(5):430–439. doi: 10.1016/j.ajog.2010.09.013
  7. Pan XY, Wang YP, Zheng Z, et al. A Marked Increase in Obstetric Hysterectomy for Placenta Accreta. Chin Med J. (Engl). 2015;128(16):2189–2193. doi: 10.4103/0366-6999.162508
  8. Russian Society of Obstetricians and Gynecologists, Russian Obstetrical Anesthesiologists and Intensivists Association, Federation of Anaesthesiologists and Reanimatologists. Prevention, management algorithm, anesthesia and intensive therapy for postpartum bleeding. Clinical guidelines. Moscow; 2018. (In Russ).
  9. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(1):27–36. doi: 10.1016/j.ajog.2017.02.050
  10. Jauniaux E, Bhide A, Kennedy A, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018;140(3):274–280. doi: 10.1002/ijgo.12408
  11. Finberg HJ, Williams JW. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section. J Ultrasound Med. 1992;11(7):333–343. doi: 10.7863/jum.1992.11.7.333
  12. Comstock CH, Love JJ Jr, Bronsteen RA, et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. Am J Obstet Gynecol. 2004;190(4):1135–1140. doi: 10.1016/j.ajog.2003.11.024
  13. Zosmer N, Jauniaux E, Bunce C, et al. Interobserver agreement on standardized ultrasound and histopathologic signs for the prenatal diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2018;140(3):326–331. doi: 10.1002/ijgo.12389
  14. Jauniaux E, Alfirevic Z, Bhide AG, et al. Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. BJOG. 2019;126(1):e1–e48. doi: 10.1111/1471-0528.15306
  15. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132(6):e259–e275. doi: 10.1097/AOG.0000000000002983
  16. Bailit JL, Grobman WA, Rice MM, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683–689. doi: 10.1097/AOG.0000000000000680
  17. Fitzpatrick KE, Sellers S, Spark P, et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;121(1):62–70; discus. 70–71. doi: 10.1111/1471-0528.12405
  18. Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123(8):1348–1355. doi: 10.1111/1471-0528.13547
  19. Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452–1458. doi: 10.1016/j.ajog.2004.05.068
  20. Smith GCS, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–1767. doi: 10.1210/jcem.87.4.8430
  21. Desai N, Krantz D, Roman A, et al. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta. Prenat Diagn. 2014;34(2):159–162. doi: 10.1002/pd.4277
  22. Thompson O, Otigbah C, Nnochiri A, Sumithran E, Spencer K. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation. BJOG. 2015;122(10):1370–1376. doi: 10.1111/1471-0528.13298
  23. Büke B, Akkaya H, Demir S, et al. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. J Matern Fetal Neonatal Med. 2018;31(1):59–62. doi: 10.1080/14767058.2016.1275546
  24. Penzhoyan GA, Makukhina TB. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders. J Perinat Med. 2019;48(1):21–26. doi: 10.1515/jpm-2019-0261
  25. Borovkov VA. Poetapnoe prognozirovanie vrastaniya platsenty u zhenshchin s rubtsom na matke [dissertation]. Barnaul; 2020. Avai lable from: https://www.dissercat.com/content/poetapnoe-prognozirovanie-vrastaniya-platsenty-u-zhenshchin-s-rubtsom-na-matke? (In Russ).
  26. Wang F, Chen S, Wang J, et al. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study. Arch Gynecol Obstet. 2021;303(3):645–652. doi: 10.1007/s00404-020-05960-1
  27. Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomar kers. Dis Markers. 2018;2018:1507674. doi: 10.1155/2018/1507674
  28. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8(1):102. doi: 10.1186/1477-7827-8-102
  29. Berndt S, Perrier d’Hauterive S, Blacher S, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 2006;20(14):2630–2632. doi: 10.1096/fj.06-5885fje
  30. Handschuh K, Guibourdenche J, Tsatsaris V, et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma. Endocrinology. 2007;148(10):5011–5019. doi: 10.1210/en.2007-0286
  31. Hung TH, Shau WY, Hsieh CC, et al. Risk factors for placenta accreta. Obstet Gynecol. 1999;93(4):545–550. doi: 10.1016/s0029-7844(98)00460-8
  32. Dreux S, Salomon LJ, Muller F, Goffinet F, Oury JF; ABA Study Group, Sentilhes L. Second-trimester maternal serum markers and placenta accreta. Prenat Diagn. 2012;32(10):1010–1012. doi: 10.1002/pd.3932
  33. Zhou J, Li J, Yan P, et al. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta. 2014;35(9):691–655. doi: 10.1016/j.placenta.2014.07.007
  34. Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. Se cond Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther. 2019;46(3):187–192. doi: 10.1159/000492829
  35. Guibourdenche J, Handschuh K, Tsatsaris V, et al. Hyperglycosylated hCG is a marker of early human trophoblast invasion. J Clin Endocrinol Metab. 2010;95(10):E240–E244. doi: 10.1210/jc.2010-0138
  36. Al-Khan A, Youssef YH, Feldman KM, et al. Biomarkers of abnormally invasive placenta. Placenta. 2020;91:37–42. doi: 10.1016/j.placenta.2020.01.007
  37. Einerson BD, Straubhar A, Soisson S, et al. Hyperglycosylated hCG and Placenta Accreta Spectrum. Am J Perinatol. 2019;36(1):22–26. doi: 10.1055/s-0038-1636501
  38. Waller DK, Lustig LS, Smith AH, Hook EB. Alpha-fetoprotein: a biomarker for pregnancy outcome. Epidemiology. 1993;4(5):471–476. doi: 10.1097/00001648-199309000-00014
  39. Oztas E, Ozler S, Caglar AT, Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy. Kaohsiung J Med Sci. 2016;32:579–585. doi: 10.1016/j.kjms.2016.08.011
  40. Ersoy AO, Oztas E, Ozler S, et al. Can venous ProBNP levels predict placenta accreta? J Matern Fetal Neonatal Med. 2016;29(24):4020–4024. doi: 10.3109/14767058.2016.1152576
  41. Shainker SA, Silver RM, Modest AM, et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2020;223(3):433.e1–433.e14. doi: 10.1016/j.ajog.2020.03.019

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86335 от 11.12.2023 г.  
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80633 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies